Translational Relevance: CXCR4 antagonists such as plerixafor (Mozobil/AMD3100) showed some efficacy in chronic lymphocyte leukemia (CLL) by distrupting the interaction between CLL and stromal cells, which lead to recirculate CLL cells towards the bloodstream. However, the therapeutic potential of CXCR4 antagonists are relatively unknown in lymphomas. Using mantle cell lymphoma as a model system, we discovered new roles of the CXCR/SDF-1 signaling axis on autophagy formation in MCL, which further promoted their survival within the bone marrow microenvironment.
other genetic or epigenetic events, possibly acting cooperatively with CCND1 overexpression, are required for the development of MCL.
Although there have been improvements in overall survival (OS), the prognosis of MCL is still one of the worst among NHL (8) . Relapsed and high-grade MCL patients often demonstrate the presence of MCL cells in other tissues, such as the bone marrow and lymphatic tissues, which are critical for disease progression (2, 3) .
Chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) is expressed by stromal marrow cells. Its receptor, CXCR4, plays critical roles in targeting hematopoietic stem cells (HSCs) within the marrow microenvironment (9) , and the CXCR4 inhibitor AMD3100 (Plerixafor) has been shown to induce significant HSC mobilization into the peripheral blood (10) . The SDF-1/CXCR4 signaling axis has been reported to play an important role in proliferation, metastasis and angiogenesis in many cancers, such as breast (11) , glioblastoma (12) , melanoma (13) , pancreatic (14) and lung (15, 16) .
Even though the presence of MCL cells in bone marrow is a negative prognosis factor for MCL patients, very limited research has been reported regarding biological mechanisms of MCL cell survival in the bone marrow (17) . In this study, we show, for the first time, that the CXCR4/SDF-1 signaling axis contributes to MCL cell survival within the bone marrow compartment via autophagy. Silencing CXCR4 in MCL cells led to decreased proliferation and colony formation, indicating that the CXCR4/SDF-1 signaling axis can contribute stem-like properties in MCL similar to its function in HSCs.
MCL colony formation was markedly increased upon co-culturing with human bone marrow stromal cells, HS27a or SDF-1. Moreover, the increase of cell survival under stressed conditions involved autophagy, an evolutionarily conserved process that Author Manuscript Published OnlineFirst on September 8, 2015 ; DOI: 10.1158/1078-0432.CCR- targets cellular materials to the lysosome for degradation. Beclin1 silencing in MCL cells led to reduced cell survival and bone marrow targeting without affecting CXCR4 cell surface expression. In summary, our study shows novel mechanisms of MCL cell survival in the bone marrow compartment and is the first report on the regulation of the CXCR4/SDF-1 signaling axis in autophagy in any cancer.
Understanding the molecular mechanisms that confer growth and dispersal to MCL cells will provide possible avenues for targeting these signaling pathways in MCL.
MATERIALS AND METHODS

Cell lines
The human mantle cell lymphoma cell lines SP-53, Jeko, Mino and Z138 were obtained 
Reagents and antibodies
Anti-CXCR4 (12G5) antibodies were purchased from BD Bioscience. Anti-LC3 (1:500) antibodies was purchased from Novus Biologicals (Littleton, CO). SDF-1 was purchased from Pepro Tech (Rocky Hill, NJ), and neutralizing antibodies against SDF-1 (MAB310) were purchased from R&D system (Minneapolis, MN). 
Lentivirus generation and transfection
293FT cells were transfected with a target plasmid containing a GFP construct and shRNA specific for human CXCR4 (V3LHS_640647, Open Biosystem, Lafayette, CO).
Vectors lacking the shRNA but containing GFP served as controls. We followed standard protocols to generate lentivirus. Briefly, 293FT cells were transfected with both pMD2.G (envelope plasmid) and psPAX2 (packaging plasmid) using calcium phosphate precipitation, and the lentiviruses were collected 48 h post transfection. Different lymphoma cell lines were infected by lentiviruses encoding the CXCR4 shRNA and were sorted 96 h post infection for GFP positive cells. Following sorting, cell lines were selected using puromycin (4 μg/mL) or blasticidin (2 μg/mL). Cells were selected for 14 days to generate stable cell lines.
Cell adhesion assay
HS27a BMSCs were seeded at a density of 5 x 10 4 cells/well in a 24-well plate and allowed to form a monolayer over 48-72 h. MCL cell lines were stained with the membrane dye PKH26 according to the manufacturer's protocol (Sigma, St. Louis, MO).
MCL cells (3 x 10
5
) suspended in 200 µL of complete RPMI1640 were then plated onto the pre-established monolayer of HS27a cells and allowed to adhere for 1 h at 37°C.
Wells were then washed twice with 1 x HBSS, and PKH26 dye intensity was measured using an Infinite®M1000 (TECAN) fluorescent plate reader. Wells containing MCL cells with no wash step served as a 100% adhesion control, while wells containing just the monolayer of HS5 cells served as a 0% adhesion control.
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Motility assay
MCL cells were stained with the membrane dye PKH26. Cells (3 x 10 4 ) were suspended in 100 µL of complete RPMI1640 were then plated onto empty 96-well plates or onto plates containing a pre-established monolayer of HS27a cells. The cells were allowed to rest for 1 h at 37°C before having their motions recorded using a time-lapse microscopy.
Time-lapse images were acquired with an Andor IXon3 885 EMCCD camera (Andor, South Windsor, CT) on an Olympus IX-81 (Olympus, Center valley, PA) microscope fitted with a microscope enclosure (Precision Plastics) maintained at 37°C with 5% CO 2 . 
Cell cytotoxicity assays
MethoCult™ colony assay
MCL cells (5000 cells) were suspended in 1 mL of complete MethoCult™ medium and plated onto 35-mm petri dishes. Colonies were maintained at 37°C with 5% CO 2 and 95% humidity for 7 days. Colonies were counted and scored at day 7, and pictures were taken using an Eclipse TE200-E microscope (Nikon). Only colonies consisting of 50 or more cells were considered for analysis.
Research. M) for 5 min. All of the procedures followed a manufacturer's protocol. Stained cells were examined for PKH expression using FACS analysis to ensure that more than 99% of the cells were PKH positive. These cells (10 6 ) were injected into irradiated (225 Gy) NOD/SCID mice, which were subsequently sacrificed after 48 h. The recovery rates of the PKH-positive cells were calculated using the following formula: % recovery = (# of PKH bright cells recovered) / (# of PKH bright cells injected).
RESULTS
The CXCR4/SDF1 signaling axis supports MCL survival under a stressed condition Although SDF-1 is a major chemokine required for early B cell development and bone marrow homing (18) , only one study has investigated the role of CXCR4, which showed a reduction of MCL migration (19) . To delineate CXCR4's biological function on MCL cells, we generated stable MCL cell lines in which their CXCR4 levels were silenced using a lentivirus encoding a CXCR4 shRNA or a control shRNA. All stable cell lines were selected for GFP expression and antibiotic resistance (Materials and Methods).
The levels of CXCR4 expression varied among different MCL cell lines, but most cells maintained a relatively high expression of CXCR4 on the surface (Supplemental The CXCR4/SDF-1 signaling axis contributes to the stem-like colony forming activities in PHA-LCM medium SDF-1 is secreted by stromal and endothelial cells in many organs (21, 22) , where it recruits CXCR4-expressing cells. We tested the effects of the CXCR4/SDF-1 signaling axis on colony forming activities using PHA-LCM (Phytohemagglutinin human leukocyte conditioned medium) conditioned medium; PHA-LCM has been used to characterize stem-like cells in multiple myeloma (23) . SDF-1 is also a chemokine critical for maintaining HSCs in adult bone marrow (24) . The addition of SDF-1 greatly increased the colony forming ability of Jeko, SP53 and Z138 MCL cells in PHA-LCM medium The bone marrow microenvironment can be divided into two distinct niches: osteoblastic and vascular. Our recent study revealed that quiescent multiple myeloma (MM) cells prefer to reside within the osteoblastic niche (25) . Therefore, we utilized a similar approach and labeled GFP-positive CXCR4 control and silenced cells with PKH26 dyes to comprehensively study the role of CXCR4/SDF-1 signaling.
To quantify the effects of CXCR4 silencing in vivo on MCL cell homing and to investigate whether CXCR4 signaling influences quiescent MCL cell engraftment to the particular niches within the bone marrow, we transplanted PKH-positive GFP-positive MCL cells into NOD/SCID mice. We allowed the PKH-labeled GFP-positive MCL cells to undergo the cell cycle within NOD/SCID mice for 48 hours before we tracked the PKHpositive cells in different niches (25) . After cycling, the remaining PKH-stained cells can be used to observe quiescent cells within a proliferating population (26, 27 ). This method has been used to study HSCs (27) as well as stem cell-like cells in breast cancer and multiple myeloma (25, 28) shRNA Jeko cells were recovered from the osteoblastic niche, 3% from the vascular niche, and 12% from the spleen compared to 6.29%, 6.96%, and 16.5% of control cells, respectively (Supplemental Table 3 and Figure 3A) . After CXCR4 silencing, PKH26-positive MCL cells recovered from the osteoblastic and the vascular niches were reduced by 55% and 56%, respectively, whereas the recovery from spleens was reduced by 26%.
Unlike the MM cells, which showed increased homing to the bone marrow compared to the spleen, higher numbers of PKH-positive MCL cells migrated to the spleen than to the bone marrow. However, after CXCR4 silencing, quiescent PKHpositive cell migration to the bone marrow was less than PKH-positive cell migration to the spleen (Supplemental Table 3 Figures 14 and 15) . It would be interesting to investigate in the future the mechanisms of SDF-1 and Ibrutinib-related MCL resistance. Collectively, our data support that CXCR4 expression is increased in bortezomib resistant MCL cells in a time-and dose-dependent manner via ROS.
Drug resistant MCL cells upregulate autophagy for survival
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved catabolic pathway in which macromolecules and organelles are sequestered into autophagosomes and subsequently fused with the lysosome, where the content is digested and recycled (33, 34) . Autophagy was reported to play a pro-survival role in MCL cells that are resistant to everolimus (RAD001), an mTOR inhibitor (35) . Since bortezomib treatment and ER stress were reported to trigger autophagy production, we investigated whether autophagy can be utilized in MCL cells as an intrinsic way to survive after bortezomib treatment. Bortezomib (30 nM) was added for varying times (0 and 24 hours) to Rec1 (bortezomib-resistant) and Jeko (bortezomib-sensitive) cells. In Figure 16) . However, bortezomib did not induce robust autophagy in bortezomib-susceptible Jeko cells ( Figure 5A) . We then generated beclin 1 knock down cells using recombinant lentivirus. GFP+ beclin 1 knock down cells demonstrated severely reduced beclin 1 expression (Supplemental Figure 17) . The induction of autophagy was diminished upon expressing beclin1 shRNA in Rec1 cells (Figure 5A ).
When the GFP-LC3 plasmid is overexpressed in cells, the expressed protein is spread diffusely throughout the cytoplasm. The induction of autophagy by nutrient starvation causes GFP-LC3 to be integrated into autophagosomes and to be displayed as punctate structures (36) . Distinct GFP-LC3 punctate structures were observed in bortezomib treated REC1 cells with low serum treatment as a positive control ( Figure   5B ). We also treated the cells with NAC to test whether reduction of ROS affects autophagy formation. Inhibiting ROS using NAC dramatically reduced autophagy formation in drug resistant MCL cells ( Figure 5C ).
CXCR4 inhibition affects autophagy formation in MCL after bortezomib treatment
Since bortezomib treatment induced CXCR4 upregulation and autophagy via ROS and (Figure 5D) , we further investigated a primary driver of survival mechanism in bortezomib resistant cells. We inhibited CXCR4 upregulation after bortezomib using AMD3100. AMD3100 treatment effectively reduced CXCR4 levels to the levels before bortezomib treatment ( Figure 5E ). Reduction of CXCR4 by AMD3100 reduced autophagy formation in Mino and REC after bortezomib treatment (Figure 5F ).
Research. Collectively, our data indicates that drug resistant MCL cells utilize not only ROS generated after drug treatment but also utilize increased CXCR4 signaling to upregulate autophagy to benefit their survival.
CXCR4 is a key signal in autophagy induction in bortezomib-sensitive MCL cells
Bortezomib treatment (30 nM) of Jeko did not increase autophagy formation ( Figure   5A ). In order to further dissect interplays between autophagy and CXCR4 in bortezomib susceptible cells, we used CXCR4 knock out Jeko cells generated by CRISPR-CAS9. While autophagy occurs at a basal level in most tissue types to promote cellular homeostasis, it is upregulated in response to nutrient starvation, hypoxia (47), oxidative stress (48, 49) , and chemotherapeutic drugs (50) . The bone marrow compartment is maintained as a highly hypoxic environment (38) , which could provide a favorable condition for the induction of autophagy. Although there are no reports directly linking hypoxia induction of autophagy in the bone morrow, several studies reported the role of hypoxia in autophagy induction in general (51, 52). Additionally, in gastric cancers, hypoxic conditions upregulate CXCR4 in a hypoxia inducible factor-1α (HIF-1α)-dependent manner (53). Together these results suggest a potential mechanism where a combined CXCR4 and hypoxia signal increases autophagy in the bone marrow; however, a detailed molecular analyses needs to be conducted to explore this potential mechanism.
High-grade MCLs often spread to the bone marrows, which provide a protective niche for the chemotherapeutic drug treatment. Our findings imply that inhibiting CXCR4 signaling or autophagy formation after ROS-inducing chemotherapies such as bortezomib will increase efficacy of the drugs. Our report is the first to show that were cultured in low serum for three days, and SDF-1 (5 ng/ml or 10 ng/ml) was added to the culture daily. The cells were evaluated using 7-AAD/Annexin V staining followed by FACS analyses. 
Chen et al.
(B) MCL cells were cultured in PHA-LCM medium with human bone marrow stromal cells, HS27a, or SDF-1 neutralizing antibodies (100 mg/ml). In some experiments, MCL cells were also cultured using stromal cells for 24 hours and collected for the colony forming assays. 
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